posted on 2022-12-21, 05:03authored byLina Gao, Meng Zhao, Yinping Mao, Lei Zhang, Xiao Wang, Simin Li, Linxi Qin, Jun Xu, Lihong Hu, Hongzhi Qiao
It has been reported that cardiac
glycosides (CGs) commonly
used
in clinical practice can inhibit tumor growth by inducing immunogenic
cell death (ICD), and their positive benefits have been documented
in several clinical trials of drug combinations. However, the inherent
cardiogenic side effects need to be addressed before CGs can be truly
applied in clinical antitumor therapy. In this study, a dual controlled
release microsphere/hydrogel platform (OL-M/Gel) was constructed to
precisely control the output of oleandrin (OL, one of the representative
CGs) in situ in tumors. With the help of this intelligent
drug release platform, OL can be released in vitro and in vivo in a sustained and stable manner. The
ability of OL to induce ICD and the subsequent antigen presentation
and cytotoxic T-cell cascades was first stated, which resulted in
potent tumor growth suppression without significant side effects.
In addition, the inhibition of autologous tumor recurrence and metastasis
by OL-M/Gel was also revealed. This study is expected to break through
the inherent bottleneck of CGs and promote their clinical transformation
in the field of antitumor treatment.